AI in Drug Discovery Conference w/ Nathan Brown

Using Artificial Intelligence to Optimise Small-Molecule Drug Design

The concept of in silico molecular design goes back decades and has a long history of published approaches using many different algorithms and models [1,2]. Major challenges involved in de novo molecular design are manifold, including identifying appropriate molecular representations for optimisation, scoring designed molecules against multiple modelled endpoints, and objectively quantifying synthetic feasibility of the designed structures.

Recently, multiobjective de novo design, more recently referred to as generative chemistry, has had a resurgence of interest. This renaissance has highlighted a step-change in successful applications of such methods. This presentation will review the development of de novo design methods over the years including the author’s original work in this area from the early 2000s [3], to recent approaches that show great promise [4,5]. Through this review, improvements in important components of de novo design, including machine learning model predictions and automated synthesis planning, will also be presented.

Register →


[1] Nicolaou, C. A., Brown, N., Pattichis, C. S. Molecular optimization using computational multi-objective methods. Current Opinion in Drug Discovery and Development, 2007, 10(3), 316-324.

[2] Nicolaou, C .A., Brown, N. Multi-objective optimization methods in drug design. Drug Discov. Today: Technol. 2013, 10(3), e427-e435.

[3] Brown, N.; McKay, B.; Gilardoni, F. A Graph-Based Genetic Algorithm and Its Application to the Multiobjective Evolution of Median Molecules. J. Chem. Inf. Comput. Sci. 2004, 44(3), 1079-1087.

[4] Neil, D.; Segler, M.; Guasch, L.; Ahmed, M.; Plumbley, D.; Sellwood, M.; Brown, N. Exploring Deep Recurrent Models with Reinforcement Learning for Molecule Design. 2018.

[5] Brown, N.; Fiscato, M.; Segler, M. H. S. Vaucher, A. C. GuacaMol: Benchmarking Models for De Novo Molecular Design. J. Chem. Inf. Model. 2019. 53(3), 1096-1108.

Nathan Brown

Director of Chemoinformatics & Computational Chemistry

Nathan is recognised as a global thought-leader in Chemoinformatics and computational drug discovery, and is the inventor of the first multiobjective de novo molecular design system. He joined BenevolentAI in 2017 from The Institute of Cancer Research, London where he founded and led the In Silico Medicinal Chemistry team for over ten years, with significant scientific impact on drugs in active clinical trials, and the development of new algorithms for drug discovery. Nathan has published over 40 papers and three books; is a Fellow of The Royal Society of Chemistry; and is the 2017 recipient of the Corwin Hansch Award.

More Posts

You Might Also Like

Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020